Thyroid dysfunction in patients (pts) with metastatic renal cell cancer (RCC) treated with sorafenib

被引：0
|
作者：
Clement, P.
Wolter, P.
Stefan, C.
Decallonne, B.
Dumez, H.
Wildiers, H.
Schoffski, P.
机构：
[1] UZ Leuven, Louvain, Belgium
[2] Katholieke Univ Leuven Hosp, Louvain, Belgium
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2008年 / 26卷 / 15期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
16145
引用
收藏
页数：1
相关论文
共 50 条
  • [21] Correlation of hypothyroidism with survival in metastatic renal cancer patients treated with sorafenib or sunitinib
    Riesenbeck, L.
    Bierer, S.
    Hoffmeister, I.
    Koepke, T.
    Hertle, L.
    Thielen, B.
    Herrmann, E.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (07)
  • [22] Sorafenib in the treatment of metastatic renal cell cancer
    Zolnierek, Jakub
    WSPOLCZESNA ONKOLOGIA-CONTEMPORARY ONCOLOGY, 2008, 12 (07): : 314 - 317
  • [23] DISEASE-RELATED SYMPTOMS OF KIDNEY CANCER IN SORAFENIB-REFRACTORY METASTATIC RENAL CELL CANCER (MRCC) PATIENTS (PTS) TREATED WITH AXITINIB (AG-013736)
    Trask, P. C.
    Mardekian, J.
    Tarazi, J.
    Bycott, P.
    Kim, S.
    Dutcher, J. P.
    Wilding, G.
    Hudes, G. R.
    Stadler, W. M.
    Rini, B.
    ANNALS OF ONCOLOGY, 2008, 19 : 192 - 192
  • [24] Comparison of kidney cancer symptoms and quality of life (QoL) in renal cell cancer (RCC) patients (pts) receiving sorafenib vs interferon-α (IFN)
    Szczylik, C.
    Cella, D.
    Eisen, T.
    Shah, S.
    Laferriere, N.
    Scheuring, U.
    Escudier, B. J.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [25] Efficacy of cabozantinib (XL184) in patients (pts) with metastatic, refractory renal cell carcinoma (RCC)
    Choueiri, Toni K.
    Pal, Sumanta Kumar
    McDermott, David F.
    Ramies, David A.
    Morrissey, Stephanie
    Lee, Yihua
    Miles, Dale
    Holland, Jaymes
    Dutcher, Janice P.
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [26] Activity of cabozantinib (XL184) in patients (pts) with metastatic, refractory renal cell carcinoma (RCC).
    Choueiri, Toni K.
    Pal, Sumanta Kumar
    McDermott, David F.
    Ramies, David A.
    Morrissey, Stephanie
    Lee, Yihua
    Miles, Dale
    Holland, Jaymes S.
    Dutcher, Janice P.
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (05)
  • [27] Sorafenib in metastatic thyroid cancer
    Capdevila, Jaume
    Iglesias, Lara
    Halperin, Irene
    Segura, Angel
    Martinez-Trufero, Javier
    Angeles Vaz, Maria
    Corral, Jesus
    Obiols, Gabriel
    Grande, Enrique
    Jose Grau, Juan
    Tabernero, Josep
    ENDOCRINE-RELATED CANCER, 2012, 19 (02) : 209 - 216
  • [28] Thyroid function tests (TFTs) abnormalities in patients (pts) with metastatic renal cell carcinoma (mRCC) treated with sunitinib.
    Shaheen, P. E.
    Tamaskar, I. R.
    Salas, R. N.
    Rini, B. I.
    Garcia, J.
    Wood, L.
    Dreicer, R.
    Bukowski, R. M.
    JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (18) : 242S - 242S
  • [29] A phase III, randomized, controlled study to compare tivozanib with sorafenib in patients (pts) with advanced renal cell carcinoma (RCC)
    Motzer, R. J.
    Bhargava, P.
    Esteves, B.
    Al-Adhami, M.
    Slichenmyer, W.
    Nosov, D.
    Eisen, T.
    Sternberg, C. N.
    Hutson, T. E.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (07)
  • [30] Treatment outcome for metastatic papillary and chromophobe renal cell carcinoma (RCC) patients treated with tyrosine-kinase inhibitors (TKIs) sunitinib and sorafenib
    Plantade, A.
    Choueiri, T.
    Escudier, B.
    Rini, B.
    Negrier, S.
    Ravaud, A.
    Oudard, S.
    Elson, P.
    Bukowski, R.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
12345